NeuroSense Therapeutics Ltd. announced a meeting with Health Canada regarding regulatory pathways for PrimeC for treating amyotrophic lateral sclerosis (ALS). The Company presented additional data to support a potential New Drug Submission (NDS) and expects to receive an official response from Health Canada from the third quarter of 2026.
